Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00367835 · ClinicalTrials.gov registry record · Phase 3
SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 217
- Enrollment target
NCT00367835 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 217 participants.
The verdict
NCT00367835, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 217 participants
- Enrollment target
Study Summary
To assess efficacy and safety of SPD503(guanfacine hydrochloride) in subjects with ADHD and oppositional symptoms.
Interventions
- DRUG Placebo
- DRUG SPD503 (Guanfacine hydrochloride)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2006-12-04 |
| Est. Completion | 2008-01-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00367835
The ClinicalTrials.gov registry entry for NCT00367835 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00367835 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00367835 about?
NCT00367835 is a clinical study titled "SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms". To assess efficacy and safety of SPD503(guanfacine hydrochloride) in subjects with ADHD and oppositional symptoms.
What is the current status of trial NCT00367835?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 217 participants. The study started on 2006-12-04. Estimated completion is 2008-01-04.
What interventions are being tested in trial NCT00367835?
The interventions under investigation include: Placebo (DRUG), SPD503 (Guanfacine hydrochloride) (DRUG).
Who is sponsoring clinical trial NCT00367835?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.